MRA Advisory Group bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,888 shares of the biopharmaceutical company’s stock, valued at approximately $245,000.
A number of other hedge funds also recently bought and sold shares of the stock. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $27,000. LGT Financial Advisors LLC grew its holdings in Bristol-Myers Squibb by 42.7% in the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 227 shares during the last quarter. Fairman Group LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $42,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at $47,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Trading Down 2.2 %
Shares of NYSE:BMY opened at $48.70 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The company has a market capitalization of $98.72 billion, a PE ratio of -15.71, a PEG ratio of 12.92 and a beta of 0.46. The business has a 50 day moving average of $45.95 and a two-hundred day moving average of $46.58. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.42.
Bristol-Myers Squibb Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 4.93%. Bristol-Myers Squibb’s payout ratio is -77.42%.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Jefferies Financial Group upped their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. TD Cowen lifted their target price on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research note on Monday, August 12th. Barclays raised their price target on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. Finally, StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $54.67.
Get Our Latest Analysis on Bristol-Myers Squibb
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also
- Five stocks we like better than Bristol-Myers Squibb
- Roth IRA Calculator: Calculate Your Potential Returns
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Conference Calls and Individual Investors
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.